Blog
RSS FeedPosted by Michael Wonder on 13 Mar 2019
Aerie Pharmaceuticals announces U.S. FDA approval of Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension
12 March 2019 - Aerie Pharmaceuticals today announced that the U.S. FDA has approved Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% ...
Posted by Michael Wonder on 12 Mar 2019
Vertex receives approval for Symdeko (tezacaftor/ivacaftor and ivacaftor) in Australia, to treat the underlying cause of cystic fibrosis in people aged 12 and older with certain CFTR gene mutations
12 March 2019 - A new treatment option for patients with two copies of the F508del mutation, the most common mutation ...
Posted by Michael Wonder on 11 Mar 2019
Cystic fibrosis breakthrough: vital drug could be made available as early as next month
8 March 2019 - A wonder drug that could dramatically improve the lives of thousands of cystic fibrosis patients may be ...
Posted by Michael Wonder on 08 Mar 2019
Campaigners call for NHS access to Orkambi as MP inquiry gets underway
8 March 2019 - Patients and campaigners took to the streets in London yesterday demanding NHS access to Vertex’ cystic ...
Posted by Michael Wonder on 08 Mar 2019
High price of cystic fibrosis drug not political, firm's boss tells MPs
8 March 2019 - CEO of company that makes Orkambi denies being ‘political minion’ for Donald Trump. ...
Posted by Michael Wonder on 05 Mar 2019
How to fix a problem like Orkambi? Solutions suggested ahead of showdown
5 March 2019 - Approaches used in France and Germany could help break deadlock. ...
Posted by Michael Wonder on 04 Mar 2019
Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry
4 March 2019 - Vertex’s long-running spat with NHS England has amounted to a legal inquiry scheduled to begin this Thursday, ...
Posted by Michael Wonder on 02 Mar 2019
New HIV drug gets cheaper with subsidies
1 March 2019 - Australians living with HIV will soon have another treatment drug available to them at a more ...
Posted by Michael Wonder on 01 Mar 2019
Esperion announces submissions of two NDAs and official completion of two MAA validations for both bempedoic acid and the bempedoic acid/ezetimibe combination tablet
28 February 2019 - Esperion today announced that the company has successfully completed important and key global marketing applications including ...
Posted by Michael Wonder on 25 Feb 2019
FDA approves Taiho Oncology's Lonsulf (trifluridine/tipiracil) for adult patients with previously treated advanced gastric or gastro-esophageal junction (GEJ) Adenocarcinoma
25 February 2019 - Taiho Oncology today announced that the United States FDA has approved Lonsulf as a treatment for adult ...
Posted by Michael Wonder on 18 Feb 2019
Bausch Health provides update for Duobrii filing
15 February 2019 - Bausch Health announced that the U.S. FDA will be unable to meet today's Prescription Drug User Fee ...
Posted by Michael Wonder on 14 Feb 2019
Cystic fibrosis breakthrough: hope for British sufferers as life-saving drug talks resume
14 February 2019 - Britain's cystic fibrosis sufferers have received fresh hope of receiving a life-saving drug after officials agreed to ...
Posted by Michael Wonder on 14 Feb 2019
New weight loss pill launched in Australia
14 February 2019 - A new medication to help fight obesity has been launched in Australia. ...
Posted by Michael Wonder on 07 Feb 2019
Vertex fears its triplet will also face UK reimbursement battle
6 February 2019 - Vertex Pharmaceuticals' cystic fibrosis business grew more than 40% in 2018, partially because of reimbursement victories in ...
Posted by Michael Wonder on 04 Feb 2019
UK patient activist group takes aim at Orkambi patent
4 February 2019 - Calls to bypass patent adds to pressure on Vertex. ...